This is one of a series of BMJ summaries of new guidelines based on the best available evidence; they highlight important recommendations for clinical practice, especially where uncertainty or controversy exists. 1 This summary of the full guidance is in two parts: part 1 on recommendations for children (up to 15 years old) and young adults (16-24 years), and part 2 on those for adults. Separate recommendations have been made for adults and for children and young people to reflect that there are different referral pathways. However, in practice young people (aged 16-24) may be referred using either an adult or children's pathway depending on their age and local arrangements. The full guidance will be available on thebmj.com.
Assessing and referring childhood cancers
Key changes in the updated guidance are:
• Reliance on new evidence derived from primary, rather than secondary, care
• Explicit use of a threshold risk of cancer to underpin recommendations for urgent investigation-the first cancer guidance to do so. • Assumes that patients will have had a full history, clinical examination, and appropriate initial blood tests
• Recommends urgent investigation in adults with a 3% or higher cancer risk, but uses a lower threshold for children and young people and when primary care testing is available
• Relies on evidence mainly from moderate quality observational studies. The evidence base for each recommendation is incorporated in the full guidance, but has been omitted here for ease of reading.
• Will increase the number of investigations or referrals in some cancer sites; the use of direct access testing should reduce the costs of this, but will require organisational change
• Asks clinicians to continue to trust their clinical experience where there are particular reasons that the guidance isn't relevant to a patient's specific presentation.
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